Peptide stacks

GLOW, KLOW, Wolverine and the topical copper peptide pairings, graded

A "stack" is two or more peptides or treatments used together, on the theory that they add up. For the five stacks below, that theory is either untested or, where it has been tested, failed: the rat study of BPC-157 with TB-500 and the human trial of GHK-Cu with microneedling both found no added benefit.^{3, 4}

All stacks

Ingredient guides: GHK-Cu · AHK-Cu · BPC-157 · TB-500 · KPV · BPC-157 vs TB-500

Why most blends fall outside the HHS policy

On October 28, 2026, HHS said it won't take enforcement action against state-licensed pharmacies, federal facilities and licensed physicians that compound six peptides: BPC-157, TB-500, KPV, MOTS-c, semax and epitalon.^{1, 2} Its conditions shut out blends in four ways:

1. One active ingredient per product. Each compounded product may contain only a single listed peptide, so BPC-157 + TB-500 in one vial is out.^{5, 6}
2. Only six peptides. GHK-Cu isn't one of them. Injectable GHK-Cu has no compounding path. FDA's advisory committee is due to review it before the end of February 2027, and a vote alone would not create one.⁷
3. Set routes. TB-500 is covered only under the skin or into muscle, and KPV only on the skin or by mouth, so an injectable with KPV is out even before the blend rule.⁵
4. Licensed makers only. 503B outsourcing facilities and products sold as research chemicals or supplements are excluded.²

That leaves pre-mixed GLOW, KLOW and Wolverine vials to "research use only" sellers. In August 2026 FDA warned five peptide sellers that the label doesn't excuse products clearly meant for people.⁸

The policy is interim, not binding and not FDA approval. Adding these peptides to the official list needs a formal rule.^{9, 7} The topical pairings (GHK-Cu with microneedling or red light) aren't compounded drugs, so the policy doesn't apply to them.

How we grade a stack

We grade the evidence for the combination itself, not for its best ingredient. A stack of three well-studied drugs that has never been tested together still scores low.

A grade measures how much evidence exists, not whether it was good news. GHK-Cu with microneedling scores 3 because it was tested in people, and the test found no benefit.

For contrast, a combination can be properly tested: cagrilintide with semaglutide (CagriSema) went through phase 3 trials in thousands of people.¹⁰

FAQ

References